Evaluation of techniques for delivery of steroids to lungs of neonates using a rabbit model

Christopher O’Callaghan, John Hardy, Julie Stammers, Terence J Stephenson, David Hull

Abstract
Little is known about delivery of aerosolised steroids to neonatal patients undergoing assisted positive pressure ventilation and after extubation. A rabbit model has been established to investigate factors influencing drug delivery.

Beclometasone dipropionate, in a metered dose inhaler, was radiolabelled with technetium 99m. The mass median aerodynamic diameter of the aerosol was 3-3 (2-0) μm and the impactor measurements confirmed that the technetium distribution corresponded with that of the drug particles. The metered dose inhaler was actuated into a collapsible spacer that was used to ventilate and deliver aerosol to anaesthetised rabbits by a tracheostomy. From each actuation of the drug 2-9 (0-4)% of the aerosol deposited in the trachea and main bronchi and 1-2 (0-4)% in the lung. When the drug was delivered by a spacer device, with facemask attachment, to rabbits breathing freely through a tracheostomy, aerosol deposition increased to 4-4 (2-1)% in the trachea and main bronchi and 1-9 (0-9)% in the lung lobes. The maximum change in systolic blood pressure after administration of aerosol by the collapsible spacer was a decrease of 13%.

The methods described may prove useful for the delivery of inhaled steroids to neonatal patients likely to develop bronchopulmonary dysplasia.

Oral steroids in the form of dexamethasone have been used with some success in the treatment of bronchopulmonary dysplasia. However, dexamethasone given over long periods may be associated with significant side effects such as prolonged suppression of the hypothalamic-pituitary-adrenal axis.

Since their introduction, inhaled steroid aerosols have become the mainstay of treatment of asthmatic patients with moderate to severe symptoms, reducing the need for large systemic doses. The considerably smaller dose used for inhalation treatment is associated with few side effects. It is postulated that low doses of inhaled steroid started early in the management of very low birthweight infants requiring ventilation may reduce the severity of bronchopulmonary dysplasia by reducing inflammation and subsequent tissue damage.

One of the conclusions from a recent workshop on aerosol treatment in the newborn was that technical problems of delivering suspended particles by aerosol need urgent solution in view of clinical demand for topical steroid treatment by aerosol in newborns. The aim of this study was to use a rabbit model to assess methods of delivery of aerosolised steroids to the airways. The results of these experiments may lead to improvements in aerosol delivery to neonatal patients.

Methods
RADIOLABELLING OF BECLOMETASONE DIPROPIONATE
Technetium 99m was used to radiolabel beclometasone dipropionate aerosol (Becotide, Allen and Hanburys). Sodium pertechnetate was extracted from saline into butanol and added to an empty beclometasone dipropionate aerosol can. The solution was evaporated to dryness and the can cooled in liquid nitrogen. A beclometasone dipropionate metered dose aerosol (50 μg/actuation;200 actuations/can) was also cooled in liquid nitrogen, opened, and the contents decanted into the can containing technetium 99m. A valve system was then crimped on to the can. At the time of dosing each can delivered approximately 1 MBq technetium 99m/actuation.

PARTICLE SIZING
A multistage liquid impinger, as described by May in 1966, and modified by Bell et al, was used to measure the aerodynamic particle size distribution of the aerosol cloud. The impinger had been calibrated by sampling an aerosol of dibutyl phthalate droplets previously sized using a reference impacter (Cassella Impacter, CF, Cassella). The radiolabelled beclometasone dipropionate preparation was fired into a Volumatic spacer device (Glaxo) with the valve closed. The spacer was plugged into the mouthpiece of the multistage liquid impinger through which air was drawn at 60 1/minute. This was repeated 25 times. The impinger was imaged using a gamma camera and the distribution of radioactivity quantified. The study was repeated under identical conditions using non-labelled beclometasone dipropionate metered dose inhalers. The impinger samples containing the drug were collected in methanol/water (50/50) and assayed against a range of known concentrations beclometasone dipropionate standards using high pressure liquid chromatography.

On the basis of the data acquired for the multistage liquid impinger, together with the 50% cut off diameter for each stage of the device, a plot of aerodynamic diameter against cumulative percentage of particles below each size was
Evaluation of techniques for delivery of steroids to lungs of neonates using a rabbit model

constructed. The graph was used to calculate the mass median aerodynamic diameter (MMAD: the droplet diameter at which half the aerosol mass is contained in smaller droplets and half in larger droplets) and the geometric standard deviation (GSD: the ratio of the 84.1% diameter to the MMAD 50% diameter). The GSD is a measure of the width of the distribution of droplet diameter.

RABBIT PREPARATION
Eight New Zealand/California rabbits were studied. A 24 gauge catheter was inserted into a marginal ear vein and anaesthesia induced with 5 ml/kg of 20% (W/V) carbamate (urethane, Sigma Chemical Co). A tracheostomy was performed and a size 3/0 endotracheal tube inserted. An 18 gauge catheter was inserted into the left carotid artery for blood pressure measurement and sampling for blood gas analysis. The catheter was kept patent by an infusion of 0-9% (W/V) saline at 1 ml/hour. Further doses of 20% (W/V) urethane were given as required up to a maximum dose of 8 ml/kg.

TIDAL VOLUME MEASUREMENT
The tidal volume of each rabbit was measured via the tracheostomy tubes connected to a 200 litre rigid container by two tubes with internal diameters of 18 mm as described by Stokes et al. A flow of 4 l/minute was conducted to the mask by a battery driven fan which was situated in one of the connecting tubes. This method eliminated any dead space in the system. A carbon dioxide absorber was included in the circuit. The pressure changes (<1 cm H_2O/10 ml) occurring within the container as a result of the rabbit’s breathing were measured by a pressure transducer (Furness Controls, FC 40) and relayed through a custom built calibration unit to a chart recorder. Calibration was carried out by injecting and withdrawing air using a 20 ml syringe.

ADMINISTRATION OF RADIOLABELLED AEROSOL TO RABBITS
(a) Via collapsible spacer device
A Laerdal resuscitation bag (Laerdal Ltd) was modified to act as a collapsible spacer. An opening was made in the base of the bag to allow access for the mouthpiece of the metered dose inhaler. The top end was fitted onto the tracheostomy tube with the rabbit lying on its back. The aerosol was then actuated into the device and immediately removed. The operators gloved hand (to protect from radioactivity on the skin) was placed over the opening at the base of the bag to act as a seal. The spacer device was then squeezed from the sides at a rate of 40/minute for 30 seconds. The pressure applied was determined by observation of adequate chest wall movement. The pressure release valve of the Laerdal resuscitation bag was left in the system for safety.

Continuous blood pressure measurements were made in the four rabbits during the procedure to determine if inflation of the rabbit chest in this manner caused hypotension due to decreased venous return to the heart.

(b) Via spacer device with facemask attachment
A Nebulizer device (Astra) with facemask attachment was used to deliver the aerosol by a 3-0 mm tracheostomy tube to anaesthetised freely breathing rabbits lying on their backs. Firm card was fitted tightly around the tracheostomy tube and the mask placed onto this to create a seal to mimic placement over an infant’s face. The spacer device was held in a vertical position above the tracheostomy and radio-labelled beclomethasone dipropionate actuated into the device. The rabbit was allowed to breathe through the mask for 30 seconds. This was repeated at 30 second intervals for a total of eight actuations. Tidal volume was measured before and after administration. Samples for blood gas analysis were also taken before drug delivery. This study was carried out in four rabbits.

MEASUREMENT OF AEROSOL DEPOSITION
Rabbits were killed immediately after the aerosol administration. The lungs and trachea were dissected out and separated into individual lobes and placed in a small plastic bag. The amount of radioactivity in each lobe and in the trachea and bronchi were assayed in a large volume sample counter. Individual lobes were weighed and cut into two parts, central and peripheral. These sections were weighed and the radioactivity measured. The amount of radioactivity from a single actuation of aerosol was collected into a plastic container at the time of each experiment and used to calibrate the equipment. The counting geometry was the same during the assay of both calibration standards and the lung specimens.

<table>
<thead>
<tr>
<th>Rabbit No</th>
<th>Weight (kg)</th>
<th>Tidal volume (ml)</th>
<th>Respiratory rate/minute*</th>
<th>pH</th>
<th>Arterial carbon dioxide tension (kPa)</th>
<th>Arterial oxygen tension (kPa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3.1</td>
<td>NR (40)</td>
<td>7.35</td>
<td>5.9</td>
<td>10.3</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>3.1</td>
<td>NR (40)</td>
<td>7.37</td>
<td>5.9</td>
<td>10.9</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>3.0</td>
<td>NR (40)</td>
<td>7.32</td>
<td>7.0</td>
<td>11.2</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>2.4</td>
<td>NR (40)</td>
<td>7.43</td>
<td>5.2</td>
<td>10.2</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>2.6</td>
<td>11 (78)</td>
<td>7.41</td>
<td>5.3</td>
<td>11.1</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>2.9</td>
<td>8 (65)</td>
<td>7.4</td>
<td>5.2</td>
<td>10.5</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>3.4</td>
<td>7 (52)</td>
<td>7.46</td>
<td>5.5</td>
<td>10.6</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>3.1</td>
<td>7 (72)</td>
<td>7.48</td>
<td>5.9</td>
<td>10.6</td>
<td></td>
</tr>
</tbody>
</table>

*Respiratory rate of rabbits 1–4 represents rate/minute at which ventilated by collapsible spacer device.
**Results**

The weight, respiratory rate, and arterial pH and carbon dioxide and oxygen tensions at the time of drug administration are recorded in table 1. Tidal volumes measured in the four rabbits given beclomethasone dipropionate by the spacer device with facemask attachment are also shown in table 1.

The percentage of beclomethasone dipropionate retained in the rabbit lung and major airways when administered by the collapsible spacer and Nebuhaler device are listed in tables 2 and 3. For each dose of beclomethasone dipropionate 2.9 (0.4%) of the aerosol deposited in the trachea and main bronchi and 1.2 (0.4%) in the lung when given by the collapsible spacer. For each dose of beclomethasone dipropionate 4.4 (2.1%) of the aerosol deposited in the trachea and main bronchi and 1.9 (0.9%) of the aerosol in the lung when given via the Nebuhaler with facemask attachment.

Deposition with in the lung lobes was calculated as the amount of aerosol per gram of tissue. Tables 4 and 5 show deposition of aerosol (proportion of total lung deposition) in the individual lung lobes expressed as a percentage of total deposition in the lungs. The right lung received more aerosol (69%) than the left lung (31%) when administered by the collapsible spacer and when given via the Nebuhaler with facemask attachment (right 64%, left 36%). More aerosol was deposited in the upper lobes (right anterior azygous, right anterior, and left anterior, 61%) than the lower lobes (right posterior, right posterior azygous, and left posterior lobe, 39%) when administered by the collapsible spacer or by the Nebuhaler with facemask attachment, 58% and 42%, respectively. When individual lobes were divided into peripheral and central portions 54 (3%) of the radiolabel deposited in the lung lobes was contained in the proximal lung tissue compared with 46 (3%) in the peripheral tissue.

The maximum change in systolic blood pressure during and after ventilation with the collapsible spacer device was 13% and the mean (SD) systolic blood pressure 106 (12) mm Hg. The MMAD (GSD) of the aerosol when determined from the technetium imaging data was 2.6 (2.1) μm and when determined by

---

**Table 2** Proportion of beclomethasone dipropionate deposited in the rabbit lung when administered by metered dose inhaler by a collapsible spacer device

<table>
<thead>
<tr>
<th>Proportion of dose (%) in rabbit No</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total aerosol in the trachea, main bronchi, and lungs</td>
<td>4.5 (3) 3.3 (3) 3.7 (4) 4.9 (0.7)</td>
</tr>
<tr>
<td>Aerosol deposited in the trachea and main bronchi</td>
<td>3.0 (2.3) 2.8 (3.3) 2.9 (0.4)</td>
</tr>
<tr>
<td>Aerosol deposited in lung</td>
<td>1.5 (1.0) 0.9 (1.6) 1.2 (0.4)</td>
</tr>
</tbody>
</table>

**Table 3** Proportion of beclomethasone dipropionate deposited in the rabbit lung when administered by metered dose inhaler by a Nebuhaler with facemask

<table>
<thead>
<tr>
<th>Proportion of dose (%) in rabbit No</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total in the trachea, main bronchi, and lungs</td>
<td>5.9 (2.9) 8.4 (8.0) 8.3 (2.5)</td>
</tr>
<tr>
<td>Aerosol deposited in the trachea and main bronchi</td>
<td>5.2 (1.3) 5.9 (5.4) 4.4 (2.1)</td>
</tr>
<tr>
<td>Aerosol deposited in lungs</td>
<td>0.7 (1.6) 2.5 (2.6) 1.9 (0.9)</td>
</tr>
</tbody>
</table>

**Table 4** Proportion of beclomethasone dipropionate aerosol given by collapsible spacer deposited in individual lung lobes

<table>
<thead>
<tr>
<th>Proportion of lung dose in each lobe (%) in rabbit No</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right anterior azygous lobe</td>
<td>24 (20) 33 (25) 25 (5)</td>
</tr>
<tr>
<td>Right anterior lobe</td>
<td>17 (11) 17 (17) 16 (3)</td>
</tr>
<tr>
<td>Right posterior lobe</td>
<td>9 (12) 16 (15) 13 (3)</td>
</tr>
<tr>
<td>Right posterior azygous lobe</td>
<td>23 (11) 11 (17) 15 (6)</td>
</tr>
<tr>
<td>Left anterior lobe</td>
<td>19 (30) 14 (16) 20 (7)</td>
</tr>
<tr>
<td>Left posterior lobe</td>
<td>9 (16) 10 (10) 11 (3)</td>
</tr>
</tbody>
</table>

**Table 5** Proportion of beclomethasone dipropionate aerosol given by nebulizer with facemask deposited in individual lung lobes

<table>
<thead>
<tr>
<th>Proportion of lung dose in each lobe (%) in rabbit No</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right anterior azygous lobe</td>
<td>35 (17) 17 (24) 23 (9)</td>
</tr>
<tr>
<td>Right anterior lobe</td>
<td>13 (12) 10 (15) 14 (3)</td>
</tr>
<tr>
<td>Right posterior lobe</td>
<td>15 (10) 20 (13) 14 (4)</td>
</tr>
<tr>
<td>Right posterior azygous lobe</td>
<td>14 (18) 6 (15) 13 (5)</td>
</tr>
<tr>
<td>Left anterior lobe</td>
<td>16 (20) 29 (20) 21 (5)</td>
</tr>
<tr>
<td>Left posterior lobe</td>
<td>12 (15) 19 (15) 15 (3)</td>
</tr>
</tbody>
</table>

---

Figure 1 Administration of beclomethasone dipropionate, by a tracheotomy, to the lungs of an anaesthetised rabbit using the collapsible spacer device.
Evaluation of techniques for delivery of steroids to lungs of neonates using a rabbit model

Discussion
The results from this pilot study are encouraging especially compared with deposition of therapeu-
tic aerosols from metered dose inhalers in adults. Assuming a 70 kg adult has a good inha-
lation technique and achieves 10% lung deposition of actuated aerosol, the dose received from
a 50μg actuation is 0.07μg/kg. When delivered
to the rabbit by the collapsible spacer (0.13
μg/kg) or via the Nebulizer with facemask (0.32
μg/kg) a considerably greater amount of beclo-
methasone dipropionate deposited in the rabbit
lungs/kg body weight. Flavin et al achieved a
lung deposition of only 0.19% in ventilated
rabbits using a traditional nebuliser. This
improved to 1.96% when the drug was delivered by
a nebuliser producing submicronic particles.
Using a nebulised cloud with a mass median
diameter of 1.3μm, Cameron et al, using standard
ventilator settings, achieved lung deposition of 2.8% of the aerosol released.
Wattenburg et al estimated that <1% of a
nebulised test dose of sodium cromoglycate
deposited in the lungs of their ventilated babies
with bronchopulmonary dysplasia.
Steroids used for nebulisation, however, are
in a suspension rather than a solution and would
not be released from a nebuliser generating
submicronic particles. Poor clinical response
seen after nebulisation of beclomethasone
dipropionate suspension in asthmatic children
may be explained by the low amount of steroid
that is contained in particles likely to reach the
airways. A suspension of budesonide, suitable
for nebulisation, has recently become available
at a concentration 10 times that of the beclo-
methasone dipropionate suspension. In a venti-
lated lung model deposition of drug ranged
from 0.06% to 2.7% depending on the nebuliser
used.
Greater deposition was seen in the upper
lobes of the rabbits, which is similar to findings
in other animal studies. This preferential deposi-
tion has been shown to be independent of body
position. Compared with instillation of drug
into the lungs, however, delivery by aerosol
results in a much more homogeneous depo-
sition.
It was encouraging that over 40% of the
drug depositing in a lung lobe reaches the outer
half. A recent study of ventilated adult patients
showed poor lung delivery after nebulisation
(1-2% of the initial dose), but much better
delivery (5-6% of initial dose) when the drug
was given from a metered dose inhaler via a
spacer chamber contained within the ventilator
circuit. Because neonates have much smaller
endotracheal tubes the percentage of the initial
total dose entering the lungs may be considerably
less. The patient does not have to be discon-
ected from the ventilator circuit, however,
which may be advantageous. In practice a
neonatal patient receiving steroid aerosol by the
collapsible spacer would have to be disconnected
only twice a day. This should prove acceptable
as ventilated babies are hand ventilated during
suction of the endotracheal tube without
apparent deleterious effect.
Once the neonatal patient is extubated, inhaled
steroids may be continued using a spacer device
with facemask attachment. Studies are required
to determine the upper airway deposition of
steroid in neonatal patients. The dose of steroid
reaching the airways of neonatal patients may be
considerably lower than seen in the present
study if there is enhanced upper airway deposi-
tion. A pilot study involving the treatment of
chronically wheezing infants with a steroid
aerosol given by a spacer device with facemask
attachment showed a very encouraging improve-
ment in symptoms. Asthmatic children aged
1-3 years have also shown improvement in
symptoms in response to steroids delivered in
this way.
The adult rabbit as a model has limitations, as
the lungs are usually normal and the pattern of
airway branching differs from that of human
airways. The model, however, provides a
simple in vivo method of comparing aerosol
deposition of various aerosols from different
devices. This is preferable to studying radio-
labelled aerosol deposition in large numbers of
neonatal patients.

1 Cummings JJ, D’Eugenio DB, Gross SJ. A controlled trial of
desmopressine in preterm infants at high risk for broncho-
2 Katz R, McWilliams B. Bronchopulmonary dysplasia in the
5 May KC. Multistage liquid impinger. *Bacteriology Reviews* 1966;30:559–70.
15 Brian JD, Knudson DE, Sorokin SP, Davis MA. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. *Environ Res* 1976;11:13–33.
Evaluation of techniques for delivery of steroids to lungs of neonates using a rabbit model.
C O'Callaghan, J Hardy, J Stammers, T J Stephenson and D Hull

Arch Dis Child 1992 67: 20-24
doi: 10.1136/adc.67.1_Spec_No.20

Updated information and services can be found at:
http://adc.bmj.com/content/67/1_Spec_No/20

Notes

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.